- Home
- MTVA vs NLSP Comparison
MTVA vs NLSP Comparison
Compare MTVA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- NLSP
- Stock Information
- Founded
- MTVA 2014
- NLSP 2015
- Country
- MTVA United States
- NLSP Switzerland
- Employees
- MTVA N/A
- NLSP N/A
- Industry
- MTVA
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- MTVA
- NLSP Health Care
- Exchange
- MTVA NYSE
- NLSP Nasdaq
- Market Cap
- MTVA 14.3M
- NLSP 12.4M
- IPO Year
- MTVA N/A
- NLSP 2021
- Fundamental
- Price
- MTVA $0.66
- NLSP $2.68
- Analyst Decision
- MTVA Strong Buy
- NLSP
- Analyst Count
- MTVA 2
- NLSP 0
- Target Price
- MTVA $7.50
- NLSP N/A
- AVG Volume (30 Days)
- MTVA 133.9K
- NLSP 325.4K
- Earning Date
- MTVA 08-13-2025
- NLSP 07-07-2025
- Dividend Yield
- MTVA N/A
- NLSP N/A
- EPS Growth
- MTVA N/A
- NLSP N/A
- EPS
- MTVA N/A
- NLSP N/A
- Revenue
- MTVA N/A
- NLSP N/A
- Revenue This Year
- MTVA N/A
- NLSP N/A
- Revenue Next Year
- MTVA N/A
- NLSP N/A
- P/E Ratio
- MTVA N/A
- NLSP N/A
- Revenue Growth
- MTVA N/A
- NLSP N/A
- 52 Week Low
- MTVA $0.63
- NLSP $1.30
- 52 Week High
- MTVA $5.30
- NLSP $16.00
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- NLSP 62.59
- Support Level
- MTVA N/A
- NLSP $2.19
- Resistance Level
- MTVA N/A
- NLSP $2.54
- Average True Range (ATR)
- MTVA 0.00
- NLSP 0.19
- MACD
- MTVA 0.00
- NLSP -0.01
- Stochastic Oscillator
- MTVA 0.00
- NLSP 57.89
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.